Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.10
Bid: 2.01
Ask: 2.10
Change: 0.065 (3.19%)
Spread: 0.09 (4.478%)
Open: 2.09
High: 2.10
Low: 2.09
Prev. Close: 2.035
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

3 Apr 2020 15:55

RNS Number : 7926I
Immupharma PLC
03 April 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Immupharma plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Lanstead Capital Investors LP

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

02/04/2020

6. Date on which issuer notified (DD/MM/YYYY):

03/04/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

20.13%

0.00%

20.13%

183,010,920

Position of previous notification (if

applicable)

13.86%

0.00%

13.86%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

 

ISIN: GB0033711010

36,843,490

0

20.13%

0.00%

SUBTOTAL 8. A

36,843,490

20.13%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

N/A

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

N/A

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

N/A

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

LON

Date of completion

03/04/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLZXLFBBZLEBBF
Date   Source Headline
8th Jul 20138:00 amRNSIMMUPHARMA APPOINTS WORLDWIDE KEY OPINION LEADERS
5th Jun 20137:00 amRNSHolding(s) in Company
23rd May 201312:29 pmRNSResult of AGM
21st May 20137:00 amRNS£50M Financing Facility - Darwin Strategic
22nd Apr 20137:00 amRNSPosting of Annual Report and AGM Notice
9th Apr 20137:00 amRNSPreliminary Results
28th Feb 20137:01 amRNSImmuPharma Commences Trading on Stuttgart Exchange
28th Jan 20134:03 pmRNSDirector/PDMR Shareholding - Replacement
28th Jan 20131:18 pmRNSDirector/PDMR Shareholding
28th Jan 20139:33 amRNSCNRS Confirms Lupuzor's (TM) Effectiveness
15th Nov 20127:30 amRNSLupuzor Presentation
5th Nov 20127:00 amRNSLupuzor Presentation
3rd Oct 20127:00 amRNSNotification of Major Interest in Shares
26th Sep 20127:01 amRNSFirst Cancer Patients in New Trial Begin Dosing
26th Sep 20127:00 amRNSInterim Results
20th Sep 20127:00 amRNSNotification of Interim Results
7th Sep 201211:12 amRNSRodman and Renshaw Conference
17th Aug 20129:11 amRNSNotification of Major Interest in Shares
11th Jul 20127:00 amRNSVoted Best Medical Research & Development Company
9th Jul 20127:00 amRNSNew Corporate Website
3rd Jul 20127:00 amRNSAppointment of Joint Broker
23rd May 201212:20 pmRNSAnnual General Meeting: 2012
17th Apr 20127:00 amRNSPosting of Annual Report and AGM Notice
27th Mar 20127:00 amRNSPreliminary Results
29th Feb 20127:00 amRNSAppoints Head of Investor Relations
24th Jan 201212:44 pmRNSDirector's Dealings
3rd Nov 20117:00 amRNSLupuzorT granted approval to start phase III
1st Nov 201110:23 amRNSNotification of Major Interest in Shares
1st Nov 201110:18 amRNSNotification of Major Interest in Shares
21st Oct 20117:00 amRNSImmuPharma regains Lupuzor rights
30th Sep 20117:00 amRNSINTERIM RESULTS ANNOUNCEMENT
23rd Sep 20119:34 amRNSNotification of Interim Results
12th Jul 20112:47 pmRNSNotification of Major Interest in Shares
19th May 201111:19 amRNSResult of Annual General Meeting
5th May 20117:00 amRNSIPP-204106 paper published
26th Apr 20114:38 pmRNSAnnual Report and Accounts & Notice of AGM
5th Apr 20117:00 amRNSPreliminary Results
30th Mar 20117:00 amRNSNotification of Preliminary Results
21st Feb 20117:00 amRNSUpdate on progress of Phase I/IIa Clinical Trial
19th Oct 20101:08 pmRNSUpdate on Phase IIa Clinical Trial
11th Oct 20102:30 pmRNSNotification of major interests in shares
11th Oct 20102:30 pmRNSAdditional Listing and Total Voting Rights
30th Sep 20107:00 amRNSInterim Results
28th Sep 201010:18 amRNSNotification of Interim Results
28th Jun 20107:00 amRNSPresentation at the International Congress
23rd Jun 20107:40 amRNSReplacement of Development release
23rd Jun 20107:00 amRNSCephalon initiates critical steps in development
17th Jun 201012:02 pmRNSResult of AGM
10th Jun 201010:55 amRNSAnnual Report and Accounts
19th May 20107:01 amRNSInitiation Of Phase I/IIA Studies In Cancer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.